FathomX develops clinician-friendly AI solutions for medical imaging, led by its flagship FxMammo product that assists mammogram screening. FxMammo has clinically validated features including reductions in false positives and interval cancers and shortens assessment time and radiologist burden. The company has integrated its AI engines into a scalable, customizable technical infrastructure and works with partners including HP Enterprise; its technology has been tested in hospitals and clinics. FathomX is advancing a multi-center validation study across eight Asia‑Pacific regions. The company intends to use new funding to accelerate product development, pursue regulatory approvals, and broaden its platform for research and commercial collaborations. In August 2022 FathomX raised a SGD$2.24M pre-Series A round; lead investors were not disclosed.

Total raised

$2M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2022